Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02385526 · ClinicalTrials.gov registry record
Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation
A clinical trial, sponsored by Cyberonics.
- Completed
- Registry status
- 67
- Enrollment target
NCT02385526: Completed study, sponsored by Cyberonics.
NCT02385526 is a clinical trial that has completed, run by Cyberonics. The registered enrollment target is 67 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02385526 has completed, sponsored by Cyberonics.
- COMPLETED
- Registry status
- 67 participants
- Enrollment target
Study Summary
Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability and clinical outcomes study to determine the number of patients achieving their final assigned VNS Therapy dose settings in patients with drug-resistant epilepsy who are being treated with adjunctive VNS Therapy using new titration protocols.
Primary Outcome
Determination of the proportion (percent) of patients in each VNS Therapy titration group reaching the defined target dose within clinically defined titration time-frame
Interventions
- DEVICE Vagus Nerve Stimulation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-04-28 |
| Est. Completion | 2016-10-10 |
What the finished NCT02385526 record still lists
NCT02385526 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 67 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Vagus Nerve Stimulation Therapy is the first listed.
NCT02385526 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02385526 about?
NCT02385526 is a clinical study titled "Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation". Post-market, on-label, double-blind, randomized, prospective, interventional, tolerability and clinical outcomes study to determine the number of patients achieving their final assigned VNS Therapy dose settings in patients with drug-resistant epilepsy who are being treated with adjunctive VNS Thera...
What is the current status of trial NCT02385526?
This trial is currently completed. The enrollment target is 67 participants. The study started on 2015-04-28. Estimated completion is 2016-10-10.
What interventions are being tested in trial NCT02385526?
The interventions under investigation include: Vagus Nerve Stimulation Therapy (DEVICE).
Who is sponsoring clinical trial NCT02385526?
This trial is sponsored by Cyberonics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI